"it seems we may now be having to educate the insurers. Like we did the fda." - I think that may take time and it will only be done via cost benefit to insurers - i.e. why waste "$150 k/yr" on Rux when most of them would result in having a Ryoncil's treatment anyway?
They will see this in their data and then will make adjustments accordingly.
We just need Ryoncil treatment to get started first though
Ann: Ryoncil Highlighted at Tandem Transplantation Meetings, page-125
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.010(0.64%) |
Mkt cap ! $2.012B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.57 | $6.922M | 4.377M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 81831 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |